Issue: 65 Page: 36-37
Combination of Feverfew, Magnesium, and Riboflavin for Migraine Prevention
by Dennis V.C. Awang
HerbalGram. 2005; 65:36-37 American Botanical Council
Combination of Feverfew, Magnesium, and Riboflavin for Migraine Prevention
Reviewed: Maizels M, Blumenfeld A, Burchette R. A
combination of riboflavin, magnesium and feverfew for migraine prophylaxis: a
randomized trial. Headache.
2004;44(9):885-890.
An advertisement in a Canadian trade publication proclaims:
“Doctors discover new hope for MIGRAINE sufferers!” The product being promoted,
MigraHealthTM (Health Assure, Sunrise, Florida), is a combination of
“magnesium, vitamin B2 (riboflavin), and a proprietary feverfew extract,
formulated by leading headache experts and neurologists.” In the ad it is
touted as “Triple Therapy” and the ad suggests that deficiencies in magnesium
and riboflavin can trigger migraine attacks.1
Both magnesium and riboflavin, with excellent safety
profiles, have shown promise as migraine prophylactics in controlled trials
(see below). Further, an uncontrolled trial found that an intravenous infusion
of magnesium sulfate caused prompt and sustained relief in roughly 50% of
patients experiencing acute migraine: a significant correlation was noted
between response and serum ionized magnesium levels.2 While the
mechanism of action of magnesium in migraine is not clearly understood, the
metal ion is known to have strong vasodilating effects which may interrupt a
vasoconstrictive phase of the migraine process; magnesium also inhibits
platelet aggregation in a dose-dependent manner.3
This study reported the
results of a randomized, double-blind, placebo-controlled trial (RCT) of a
combination formulation, the daily dose of which provided 400 mg riboflavin,
300 mg magnesium, and 100 mg of a proprietary feverfew extract; the “placebo”
contained 25 mg riboflavin. This product has the same combination of ingredients
as the advertised MigraHealthTM and gives no indication as to the
manner of preparation of the feverfew extract. (It is interesting to note that
of the three trials of extracts of feverfew leaf, two employed supercritical CO2
extracts4,5 and were successful, whereas an extract produced from
protracted extraction [19 days] with 90% ethanol was unsuccessful in migraine
prophylaxis.6)
The results of this recent RCT are intriguing since the
“placebo” response exceeded that reported for any other placebo in trials of
migraine prophylaxis, suggesting that 25 mg riboflavin was an active
comparator. Of the 49 patients who completed the 3-month trial, there was no
significant difference noted between verum (the feverfew combination) and
“placebo” groups. For the primary outcome measure, a 50% or greater reduction
in migraines was achieved by 10 (42%) and 11 (44%) subjects, respectively.
There was also no significant difference between the 2 groups respecting the
secondary outcome measures of 50% or greater reduction in migraine days or
change in mean number of migraines, migraine index, or triptan doses, being 33%
and 40%, respectively. There is a clear indication from these observations that
400 mg riboflavin daily is no better than 25 mg, and that magnesium and this
feverfew extract made no perceptible contribution to the anti-migraine effect
of the tested formulation. The single positive RCT so far conducted with
riboflavin involved a daily dose of 400 mg.7 This further suggests
that the feverfew extract may not have been properly prepared, since there was
no enhancement of prophylactic effect by addition of the extract.
Regarding magnesium, oral supplementation has been found
effective in 2 of 3 RCTs. In a trial of 24 women with menstrual migraine,8
subjects received magnesium pyrrolidone carboxylic acid 3 times daily
(equivalent to 360 mg magnesium ion daily) or placebo from the 15th day of
their cycle until menses. The women taking the magnesium supplement experienced significantly less pain and
reduced number of days with headache than the placebo group. In the second
positive study, 81 patients, aged 18 to 65 years, received either magnesium
(600 mg trimagnesium dicitrate daily) or placebo for 12 weeks.9 The
frequency of migraine attacks was reduced by 42% and 16%, respectively, while
the number of days with migraine was significantly reduced only in the treated
group. The third trial of 69 subjects showed no benefit from a daily dose of
500 mg magnesium over placebo for 12 weeks.10
Based on the trials summarized above, it seems possible that
the amount of magnesium in the feverfew combination product (360 mg/day) was
not sufficiently large to exert a prophylactic effect. The reason for the
failure of the third magnesium trial10 (500 mg/day) is not
apparent.
A fundamental problem in the trial of combination products
is that trials of such products are often conducted without the activity of all constituents having been
established individually. It appears that the specific feverfew extract
employed in this recent trial had not been clinically tested to determine its
efficacy. So far there have been three positive trials recorded that use
encapsulated dried feverfew leaf of a parthenolide-dominant sesquiterpene
lactone chemotype; however, it is quite evident that parthenolide is not a
direct appreciable anti-migraine principle,11 though conspicuously
still regarded in some quarters as the main feverfew active in that respect.
– Dennis V.C. Awang, PhD, FCIC
MediPlant Consulting Inc., White Rock, Canada
References
1. Advertisement Supplement, The Vancouver Sun, November 6, 2004.
2. Mauskop A, Altura BT, Cracco RQ, Attura BM. Intravenous
magnesium soleplate relieves migraine attacks in patients with low serum
ionized magnesium levels: a pilot study. Clin Sci (Lond). 1995; 89(6):663-666.
3. Fugh-Berman A. Dietary supplements for migraine:
magnesium and riboflavin. Alternative Therapies in Women’s Health. 1999;1(3):17-19.
4. Pfaffenrath V, Diener HC, Fischer M, Friede M,
Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a double-blind,
multicentre, randomized placebo-controlled dose-response study. Cephalalgia. 2002;22:523-532.
5. Diener HC, Pfaffenrath J, Schnitker J, Friede M,
Henneicke-von Zepelin H-H. Efficacy and safety of 6.25 mg tid feverfew-CO2-extract
(MIG-99) in migraine prevention – A randomized, double-blind, multicentre,
placebo-controlled study. Cephalalgia.
In press.
6. de Weerdt CJ, Bootsma HPR, Hendriks H. Randomized
double-blind placebo-controlled trial of a feverfew preparation. Phytomedicine. 1996;3(3):225-230.
7. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of
high-dose riboflavin in migraine prophylaxis. Neurology. 1998;50:466-470.
8. Facchinetti F, Sances G, Norella P, Gennazzani AR, Nappi
G. Magnesium prophylaxis of menstrual migraine. Effects on intracellular
magnesium. Headache. 1991;31:298-301.
9. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of
migraine with oral magnesium. Results from a prospective, multi-center, placebo-controlled
and double-blind randomized study. Cephalalgia. 1996;16:257-263.
10. Pfaffenrath V, Wesseley P, Meyer C, Isler HR, Evers S,
Grotemeyer KH, et al. Magnesium in
the prophylaxis of migraine – a double-blind, placebo-controlled study. Cephalalgia. 1996;6:436-440.
11. Awang DVC. Prescribing therapeutic feverfew [(Tanacetum parthenium
(L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.)].
Integrative Medicine. 1998;1(1):11-13.
|